{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:52:16Z","timestamp":1787503936460,"version":"build-2736575974"},"reference-count":172,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":220,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetics have higher morbidity and mortality in cardiovascular disease (CVD). A variety of antidiabetic agents are available for clinical choice. Cardiovascular (CV) safety assessment of these agents is crucial in addition to hypoglycemic effect before clinical prescription. Adenosine 5\u2032-monophosphate-activated protein kinase (AMPK) is an important cell energy sensor, which plays an important role in regulating myocardial energy metabolism, reducing ischemia and ischemia\/reperfusion (I\/R) injury, improving heart failure (HF) and ventricular remodeling, ameliorating vascular endothelial dysfunction, antichronic inflammation, anti-apoptosis, and regulating autophagy. In this review, we summarized the effects of antidiabetic agents to CVD according to basic and clinical research evidence and put emphasis on whether these agents can play roles in CV system through AMPK-dependent signaling pathways. Metformin has displayed definite CV benefits related to AMPK. Sodium-glucose cotransporter 2 inhibitors also demonstrate sufficient clinical evidence for CV protection, but the mechanisms need further exploration. Glucagon-likepeptide1 analogs, dipeptidyl peptidase-4 inhibitors, \u03b1-glucosidase inhibitors and thiazolidinediones also show some AMPK-dependent CV benefits. Sulfonylureas and meglitinides may be unfavorable to CV system. AMPK is becoming a promising target for the treatment of diabetes, metabolic syndrome and CVD. But there are still some questions to be answered.<\/jats:p>","DOI":"10.1042\/bsr20181995","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:55:57Z","timestamp":1549022157000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases"],"prefix":"10.1042","volume":"39","author":[{"given":"Qingguo","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, 610041 Chengdu, China"},{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."},{"name":"Department of Geriatrics, The First Hospital of Jilin University, 130021 Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."},{"name":"Department of Endocrinology, Affiliated Hospital of Weifang Medical University, 261000 Weifang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rousselle","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanwei","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, 610041 Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, 39216 Jackson, MS, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2019102503290900700_B1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2019102503290900700_B2","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.109.913350","article-title":"Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data","volume":"122","author":"Mazzone","year":"2010","journal-title":"Circulation"},{"key":"2019102503290900700_B3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"key":"2019102503290900700_B4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 Diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B5","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B6","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"2019102503290900700_B7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.110.953208","article-title":"Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart","volume":"122","author":"Ma","year":"2010","journal-title":"Circulation"},{"key":"2019102503290900700_B8","first-page":"732","article-title":"Diabetic cardiomyopathy","volume":"11","author":"Acar","year":"2011","journal-title":"Anadolu Kardiyol. Derg."},{"key":"2019102503290900700_B9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/VHRM.S11681","article-title":"Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies","volume":"6","author":"Voulgari","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"2019102503290900700_B10","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1242\/jcs.01540","article-title":"The AMP-activated protein kinase pathway\u2013new players upstream and downstream","volume":"117","author":"Hardie","year":"2004","journal-title":"J. Cell Sci."},{"key":"2019102503290900700_B11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1432-1033.1997.00259.x","article-title":"The AMP-activated protein kinase\u2013fuel gauge of the mammalian cell?","volume":"246","author":"Hardie","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"2019102503290900700_B12","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1172\/JCI67227","article-title":"AMPK, insulin resistance, and the metabolic syndrome","volume":"123","author":"Ruderman","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2019102503290900700_B13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in health and disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol. Rev."},{"key":"2019102503290900700_B14","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.cub.2003.10.031","article-title":"LKB1 is the upstream kinase in the AMP-activated protein kinase cascade","volume":"13","author":"Woods","year":"2003","journal-title":"Curr. Biol."},{"key":"2019102503290900700_B15","doi-asserted-by":"publisher","first-page":"29060","DOI":"10.1074\/jbc.M503824200","article-title":"The Ca2+\/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases","volume":"280","author":"Hurley","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B16","doi-asserted-by":"publisher","first-page":"H239","DOI":"10.1152\/ajpheart.01269.2005","article-title":"AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B","volume":"291","author":"Bertrand","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B17","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/db12-0533","article-title":"Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes","volume":"62","author":"He","year":"2013","journal-title":"Diabetes"},{"key":"2019102503290900700_B18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nature06504","article-title":"Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart","volume":"451","author":"Miller","year":"2008","journal-title":"Nature"},{"key":"2019102503290900700_B19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1172\/JCI19297","article-title":"AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury","volume":"114","author":"Russell","year":"2004","journal-title":"J. Clin. Invest."},{"key":"2019102503290900700_B20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1538-7836.2011.04331.x","article-title":"Activated protein C protects against myocardial ischemic\/reperfusion injury through AMP-activated protein kinase signaling","volume":"9","author":"Wang","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"2019102503290900700_B21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.metabol.2018.03.004","article-title":"Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-kappaB pathway","volume":"83","author":"Chen","year":"2018","journal-title":"Metabolism"},{"key":"2019102503290900700_B22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2337\/db14-0576","article-title":"Role of Epac2A\/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion","volume":"64","author":"Takahashi","year":"2015","journal-title":"Diabetes"},{"key":"2019102503290900700_B23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/euhj.1999.1999","article-title":"Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)","volume":"21","author":"Klamann","year":"2000","journal-title":"Eur. Heart J."},{"key":"2019102503290900700_B24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2019102503290900700_B25","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur. Heart J."},{"key":"2019102503290900700_B26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jacc.2004.05.060","article-title":"Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways","volume":"44","author":"Yang","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019102503290900700_B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/meta.2000.17822","article-title":"Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues","volume":"49","author":"Gribble","year":"2000","journal-title":"Metabolism"},{"key":"2019102503290900700_B28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jash.2012.02.003","article-title":"Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies","volume":"6","author":"Brown","year":"2012","journal-title":"J. Am. Soc. Hypertens."},{"key":"2019102503290900700_B29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/B:CARD.0000029028.75316.5e","article-title":"Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide","volume":"18","author":"Maddock","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2019102503290900700_B30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1210\/jc.2002-020904","article-title":"Impairment of myocardial protection in type 2 diabetic patients","volume":"88","author":"Lee","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2019102503290900700_B31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1159\/000481638","article-title":"Glibenclamide mimics metabolic effects of metformin in H9c2 cells","volume":"43","author":"Salani","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"2019102503290900700_B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.vph.2018.01.001","article-title":"Gliclazide, a KATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKbeta-AMPK pathway","volume":"102","author":"Lee","year":"2018","journal-title":"Vascul. Pharmacol."},{"key":"2019102503290900700_B33","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.chembiol.2012.08.019","article-title":"AMP-activated protein kinase: a target for drugs both ancient and modern","volume":"19","author":"Hardie","year":"2012","journal-title":"Chem. Biol."},{"key":"2019102503290900700_B34","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018","volume":"41","author":"American Diabetes A","year":"2018","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B36","doi-asserted-by":"publisher","first-page":"b1668","DOI":"10.1136\/bmj.b1668","article-title":"Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance","volume":"338","author":"Adler","year":"2009","journal-title":"BMJ"},{"key":"2019102503290900700_B37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"2019102503290900700_B38","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","article-title":"Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes","volume":"25","author":"Johnson","year":"2002","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B39","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc10-0017","article-title":"The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis","volume":"33","author":"Pantalone","year":"2010","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"2019102503290900700_B41","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2019102503290900700_B42","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"2019102503290900700_B43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"2019102503290900700_B44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest."},{"key":"2019102503290900700_B45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"key":"2019102503290900700_B46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4161\/auto.7.10.16740","article-title":"AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy","volume":"7","author":"Xie","year":"2011","journal-title":"Autophagy"},{"key":"2019102503290900700_B48","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.2337\/diabetes.51.8.2420","article-title":"The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism","volume":"51","author":"Hawley","year":"2002","journal-title":"Diabetes"},{"key":"2019102503290900700_B49","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1053\/j.gastro.2006.03.020","article-title":"Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1","volume":"130","author":"Bergheim","year":"2006","journal-title":"Gastroenterology"},{"key":"2019102503290900700_B50","doi-asserted-by":"publisher","first-page":"H2497","DOI":"10.1152\/ajpheart.00873.2007","article-title":"Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms","volume":"294","author":"Saeedi","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B51","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1210\/en.2003-0849","article-title":"Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity","volume":"144","author":"Ruderman","year":"2003","journal-title":"Endocrinology"},{"key":"2019102503290900700_B52","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.2337\/diabetes.48.8.1667","article-title":"5\u2032 AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle","volume":"48","author":"Kurth-Kraczek","year":"1999","journal-title":"Diabetes"},{"key":"2019102503290900700_B53","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1210\/en.2005-1433","article-title":"Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis","volume":"147","author":"Yang","year":"2006","journal-title":"Endocrinology"},{"key":"2019102503290900700_B54","doi-asserted-by":"publisher","first-page":"H457","DOI":"10.1152\/ajpheart.00002.2007","article-title":"Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration","volume":"293","author":"Zhang","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B55","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/0006-291X(83)90366-2","article-title":"Photoaffinity cross-linking of oligomycin-sensitive ATPase from beef heart mitochondria by 3\u2032-arylazido-8-azido ATP","volume":"111","author":"Schafer","year":"1983","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2019102503290900700_B56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.biopha.2017.12.023","article-title":"Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control","volume":"98","author":"Sambe","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"2019102503290900700_B57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/diabetes.55.01.06.db05-0943","article-title":"Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells","volume":"55","author":"Kukidome","year":"2006","journal-title":"Diabetes"},{"key":"2019102503290900700_B58","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2337\/db07-1098","article-title":"Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling","volume":"57","author":"Calvert","year":"2008","journal-title":"Diabetes"},{"key":"2019102503290900700_B59","doi-asserted-by":"crossref","first-page":"43940","DOI":"10.1074\/jbc.M404421200","article-title":"Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species","volume":"279","author":"Zou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2337\/diabetes.55.02.06.db05-1064","article-title":"Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase","volume":"55","author":"Davis","year":"2006","journal-title":"Diabetes"},{"key":"2019102503290900700_B61","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.mehy.2004.01.042","article-title":"AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome","volume":"64","author":"McCarty","year":"2005","journal-title":"Med. Hypotheses"},{"key":"2019102503290900700_B62","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s11427-017-9285-1","article-title":"A potential strategy for treating atherosclerosis: improving endothelial function via AMP-activated protein kinase","volume":"61","author":"Gao","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"2019102503290900700_B63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.freeradbiomed.2018.02.031","article-title":"Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis","volume":"118","author":"Gopoju","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"2019102503290900700_B64","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0735-1097(03)00647-8","article-title":"Diabetic cardiomyopathy. the importance of being earliest","volume":"42","author":"Picano","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019102503290900700_B65","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"2019102503290900700_B66","first-page":"99","article-title":"Metformin: safety in cardiac patients","volume":"96","author":"Khurana","year":"2010","journal-title":"Heart"},{"key":"2019102503290900700_B67","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.2337\/dc07-1686","article-title":"Metformin in heart failure","volume":"30","author":"Inzucchi","year":"2007","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B68","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/bmj.39255.669444.AE","article-title":"Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?","volume":"335","author":"Tahrani","year":"2007","journal-title":"BMJ"},{"key":"2019102503290900700_B69","doi-asserted-by":"publisher","first-page":"H459","DOI":"10.1152\/ajpheart.00054.2011","article-title":"Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure","volume":"301","author":"Yin","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.tem.2014.11.001","article-title":"Is AMPK the savior of the failing heart?","volume":"26","author":"Kim","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"2019102503290900700_B71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40256-018-0266-3","article-title":"Cardioprotection by metformin: beneficial effects beyond glucose reduction","volume":"18","author":"Varjabedian","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"2019102503290900700_B72","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"key":"2019102503290900700_B73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ. Res."},{"key":"2019102503290900700_B74","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"2019102503290900700_B75","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1440-1681.2010.05470.x","article-title":"Metformin improves cardiac function in rats via activation of AMP-activated protein kinase","volume":"38","author":"Wang","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2019102503290900700_B76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00395-011-0216-6","article-title":"The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury","volume":"106","author":"Ye","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"2019102503290900700_B77","doi-asserted-by":"publisher","first-page":"2961954","DOI":"10.1155\/2016\/2961954","article-title":"Metformin protects H9C2 cardiomyocytes from high-glucose and hypoxia\/reoxygenation injury via inhibition of reactive oxygen species generation and inflammatory responses: role of AMPK and JNK","volume":"2016","author":"Hu","year":"2016","journal-title":"J. Diabetes Res."},{"key":"2019102503290900700_B78","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FJC.0b013e31819fd4e7","article-title":"Metformin prevents myocardial reperfusion injury by activating the adenosine receptor","volume":"53","author":"Paiva","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2019102503290900700_B79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10557-010-6222-3","article-title":"Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction","volume":"24","author":"Paiva","year":"2010","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2019102503290900700_B80","first-page":"423","article-title":"A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection","volume":"84","author":"Chin","year":"2011","journal-title":"Yale J. Biol. Med."},{"key":"2019102503290900700_B81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: its potential beyond glucose-lowering effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr. Metab. Immune. Disord. Drug Targets"},{"key":"2019102503290900700_B82","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.intimp.2012.10.014","article-title":"Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected?","volume":"14","author":"Soraya","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"2019102503290900700_B83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejphar.2014.05.003","article-title":"Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction","volume":"737","author":"Soraya","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"2019102503290900700_B84","doi-asserted-by":"publisher","first-page":"130636","DOI":"10.1155\/2010\/130636","article-title":"AMP-activated protein kinase activation during cardioplegia-induced hypoxia\/reoxygenation injury attenuates cardiomyocytic apoptosis via reduction of endoplasmic reticulum stress","volume":"2010","author":"Yeh","year":"2010","journal-title":"Mediators Inflamm."},{"key":"2019102503290900700_B85","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1007\/s00125-006-0338-9","article-title":"Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3","volume":"49","author":"An","year":"2006","journal-title":"Diabetologia"},{"key":"2019102503290900700_B86","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.freeradbiomed.2011.08.015","article-title":"Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system","volume":"51","author":"Asensio-Lopez","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"2019102503290900700_B87","doi-asserted-by":"publisher","first-page":"e104888","DOI":"10.1371\/journal.pone.0104888","article-title":"Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study","volume":"9","author":"Kobashigawa","year":"2014","journal-title":"PLoS ONE"},{"key":"2019102503290900700_B88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2697","article-title":"Autophagy: cellular and molecular mechanisms","volume":"221","author":"Glick","year":"2010","journal-title":"J. Pathol."},{"key":"2019102503290900700_B89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bbadis.2014.09.002","article-title":"Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1-AMPK signaling and autophagy","volume":"1852","author":"Roe","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"2019102503290900700_B90","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.2174\/138161209789057995","article-title":"Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?","volume":"15","author":"Papanas","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"2019102503290900700_B91","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00149831-200410000-00009","article-title":"Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy","volume":"11","author":"Zeymer","year":"2004","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"2019102503290900700_B92","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/01.STR.0000125864.01546.f2","article-title":"Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance","volume":"35","author":"Hanefeld","year":"2004","journal-title":"Stroke"},{"key":"2019102503290900700_B93","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1253\/circj.CJ-11-1524","article-title":"Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes","volume":"76","author":"Hirano","year":"2012","journal-title":"Circ. J."},{"key":"2019102503290900700_B94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":"Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur. Heart J."},{"key":"2019102503290900700_B95","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/FJC.0b013e3181a98b53","article-title":"Acarbose reduces myocardial infarct size by preventing postprandial hyperglycemia and hydroxyl radical production and opening mitochondrial KATP channels in rabbits","volume":"54","author":"Minatoguchi","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2019102503290900700_B96","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0026-0495(99)90168-3","article-title":"Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099)","volume":"48","author":"Russell","year":"1999","journal-title":"Metabolism"},{"key":"2019102503290900700_B97","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.bjp.0705863","article-title":"Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia\/reperfusion rabbit heart","volume":"142","author":"Wang","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"2019102503290900700_B98","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/FJC.0b013e3181dcd240","article-title":"Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits","volume":"55","author":"Iwasa","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2019102503290900700_B99","doi-asserted-by":"publisher","first-page":"38642","DOI":"10.1038\/srep38642","article-title":"Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"2019102503290900700_B100","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1254\/jphs.12108FP","article-title":"Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase","volume":"120","author":"Aoki","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"2019102503290900700_B101","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1021\/jf062680g","article-title":"Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans","volume":"55","author":"Kimura","year":"2007","journal-title":"J. Agric. Food Chem."},{"key":"2019102503290900700_B102","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3164\/jcbn.10-53","article-title":"Effects of mulberry leaf extract rich in 1-deoxynojirimycin on blood lipid profiles in humans","volume":"47","author":"Kojima","year":"2010","journal-title":"J. Clin. Biochem. Nutr."},{"key":"2019102503290900700_B103","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.1021\/jf403636z","article-title":"Mulberry 1-deoxynojirimycin pleiotropically inhibits glucose-stimulated vascular smooth muscle cell migration by activation of AMPK\/RhoB and down-regulation of FAK","volume":"61","author":"Chan","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"2019102503290900700_B104","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"2019102503290900700_B105","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"2019102503290900700_B106","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.amjcard.2003.10.022","article-title":"Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome","volume":"93","author":"Wang","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"2019102503290900700_B107","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"2019102503290900700_B108","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"2019102503290900700_B109","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B110","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMp1309610","article-title":"The cardiovascular safety of diabetes drugs\u2013insights from the rosiglitazone experience","volume":"369","author":"Hiatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B111","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B112","doi-asserted-by":"publisher","first-page":"25226","DOI":"10.1074\/jbc.M202489200","article-title":"The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways","volume":"277","author":"Fryer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B113","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease","volume":"19","author":"Schneider","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2019102503290900700_B114","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2337\/db05-1315","article-title":"Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats","volume":"55","author":"Ye","year":"2006","journal-title":"Diabetes"},{"key":"2019102503290900700_B115","doi-asserted-by":"publisher","first-page":"16309","DOI":"10.1073\/pnas.222657499","article-title":"Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation","volume":"99","author":"Tomas","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2019102503290900700_B116","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1074\/jbc.M505311200","article-title":"Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists","volume":"281","author":"Nawrocki","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2019102503290900700_B117","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes"},{"key":"2019102503290900700_B118","doi-asserted-by":"publisher","first-page":"H895","DOI":"10.1152\/ajpheart.00137.2011","article-title":"Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice","volume":"301","author":"Morrison","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B119","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/nm1137","article-title":"Adiponectin-mediated modulation of hypertrophic signals in the heart","volume":"10","author":"Shibata","year":"2004","journal-title":"Nat. Med."},{"key":"2019102503290900700_B120","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.109.141655","article-title":"Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone","volume":"55","author":"Li","year":"2010","journal-title":"Hypertension"},{"key":"2019102503290900700_B121","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0b013e328302f0f7","article-title":"Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt","volume":"26","author":"Kato","year":"2008","journal-title":"J. Hypertens."},{"key":"2019102503290900700_B122","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jnutbio.2009.03.011","article-title":"Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase","volume":"21","author":"Xiao","year":"2010","journal-title":"J. Nutr. Biochem."},{"key":"2019102503290900700_B123","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/MCB.20.5.1868-1876.2000","article-title":"The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes","volume":"20","author":"Vega","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"2019102503290900700_B124","doi-asserted-by":"publisher","first-page":"R429","DOI":"10.1152\/ajpregu.00431.2013","article-title":"Exposure to rosiglitazone, a PPAR-gamma agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus","volume":"306","author":"Lie","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2019102503290900700_B125","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"2019102503290900700_B126","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2019102503290900700_B127","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B128","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"Sivertsen","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"key":"2019102503290900700_B129","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B130","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B131","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"2019102503290900700_B132","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"2019102503290900700_B133","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"2019102503290900700_B134","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1758-5996-6-29","article-title":"Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats","volume":"6","author":"Guo","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"2019102503290900700_B135","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.bbrc.2015.09.179","article-title":"Exendin-4 attenuates cardiac hypertrophy via AMPK\/mTOR signaling pathway activation","volume":"468","author":"Zhou","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2019102503290900700_B136","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.mce.2017.03.029","article-title":"Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat","volume":"448","author":"Zhang","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"2019102503290900700_B137","doi-asserted-by":"publisher","first-page":"H1120","DOI":"10.1152\/ajpheart.00210.2014","article-title":"AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes","volume":"307","author":"Balteau","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B138","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00210-017-1414-z","article-title":"Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt\/GSK-3beta signaling pathway","volume":"390","author":"Abbas","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2019102503290900700_B139","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2015.03.026","article-title":"GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats","volume":"240","author":"Inoue","year":"2015","journal-title":"Atherosclerosis"},{"key":"2019102503290900700_B140","doi-asserted-by":"publisher","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS ONE"},{"key":"2019102503290900700_B141","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2019102503290900700_B142","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"2019102503290900700_B143","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B144","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B145","doi-asserted-by":"publisher","first-page":"H1454","DOI":"10.1152\/ajpheart.00867.2009","article-title":"The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA","volume":"298","author":"Ye","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2019102503290900700_B146","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10557-010-6271-7","article-title":"Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats","volume":"25","author":"Huisamen","year":"2011","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2019102503290900700_B147","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00125-012-2582-5","article-title":"Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-\/-) mice","volume":"55","author":"Vittone","year":"2012","journal-title":"Diabetologia"},{"key":"2019102503290900700_B148","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"2019102503290900700_B149","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1475-2840-13-32","article-title":"The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms","volume":"13","author":"Zeng","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"2019102503290900700_B150","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3892\/ijmm.2016.2578","article-title":"Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-kappaB\/IkappaBalpha system through the activation of AMP-activated protein kinase","volume":"37","author":"Tang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"2019102503290900700_B151","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3892\/mmr.2017.6501","article-title":"Dipeptidyl peptidase4 inhibitor sitagliptin prevents high glucoseinduced apoptosis via activation of AMPactivated protein kinase in endothelial cells","volume":"15","author":"Wu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"2019102503290900700_B152","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopha.2018.07.126","article-title":"Sitagliptin attenuates myocardial apoptosis via activating LKB-1\/AMPK\/Akt pathway and suppressing the activity of GSK-3beta and p38alpha\/MAPK in a rat model of diabetic cardiomyopathy","volume":"107","author":"Al-Damry","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"2019102503290900700_B153","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.yjmcc.2011.08.001","article-title":"Effects of DPP-4 inhibition on cardiac metabolism and function in mice","volume":"51","author":"Lenski","year":"2011","journal-title":"J. Mol. Cell Cardiol."},{"key":"2019102503290900700_B154","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B155","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"2019102503290900700_B156","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2019102503290900700_B157","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0005-2760(94)00082-4","article-title":"Regulation of fatty acid oxidation in the mammalian heart in health and disease","volume":"1213","author":"Lopaschuk","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"2019102503290900700_B158","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: the sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"2019102503290900700_B159","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2019102503290900700_B160","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"2019102503290900700_B161","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2019102503290900700_B162","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 Inhibitors May Predispose to Ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2019102503290900700_B163","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"2019102503290900700_B164","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2019102503290900700_B165","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"2019102503290900700_B166","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1159\/000475942","article-title":"The sodium-glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway","volume":"41","author":"Zhou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"2019102503290900700_B167","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front. Physiol."},{"key":"2019102503290900700_B168","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","article-title":"Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes","volume":"31","author":"Hammoudi","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2019102503290900700_B169","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db16-0733","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model","volume":"66","author":"Joubert","year":"2017","journal-title":"Diabetes"},{"key":"2019102503290900700_B170","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"2019102503290900700_B171","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci. Rep."},{"key":"2019102503290900700_B172","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox. Biol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181995\/844595\/bsr-2018-1995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181995\/844595\/bsr-2018-1995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T03:33:44Z","timestamp":1571974424000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/doi\/10.1042\/BSR20181995\/110904\/AMPK-is-associated-with-the-beneficial-effects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":172,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181995","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s13205-025-04395-2","asserted-by":"object"}]},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2]]},"article-number":"BSR20181995"}}